x

Posted 29 April, 2022

IR-Med, Inc. appointed new CEO

CEO Change detected for ticker OTC:IRME in a 8-K filed on 29 April, 2022.


  (b) On April 25, 2022, IR-Med, Inc. (the "Company") received notice that Dr. Rom Rliaz would be resigning from his role as Chief Executive Officer of the Company to pursue personal interests.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of IR-Med, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
IR-Med, Inc. is engaged in the designing and developing devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company was founded by Ronnie Klein and Yaniv Cohen in April 2007 and is headquartered in Rosh Haayin, Israel.
Market Cap
$101M
View Company Details
IR-Med, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On April 25, 2022, IR-Med, Inc. (the "Company") received notice that Dr. Rom Rliaz would be resigning from his role as Chief Executive Officer of the Company to pursue personal interests. Dr. Eliaz's resignation will be effective as of April 30, 2022. Dr. Eliaz's resignation was not associated with or attributable to any disagreement with the Company or the Company's independent auditor, including without limitation, any matter relating to the Company's accounting principles or practices, financial statement disclosures, internal controls, management or operations.

In connection with his resignation, the Company agreed that Dr. Eliaz will continue to receive his salary and benefits under his employment agreement through August 31, 2022. In addition, the Company agreed that Dr. Eliaz is entitled to the accelerated vesting of the next instalment of options (previously granted to in June 2021) scheduled to vest on June 30, 2022, for an aggregate total of options for 150,000 shares of the Company's common stock and that such options may be exercised through the original exercise expiry date (i.e., July 31, 2027) at the exercise price per share of $0.32.